Yiyun Tang
Southwest University(CN)Minzu University of China(CN)Pfizer (United States)(US)Huntsman Cancer Institute(US)Chengdu University of Technology(CN)Hainan Medical University(CN)University of South China(CN)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Lung Cancer Treatments and Mutations, Cancer, Lipids, and Metabolism, Prostate Cancer Diagnosis and Treatment, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study(2012)1,275 cited
- → Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis(2011)896 cited
- → Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer(2018)409 cited
- → Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer(2023)254 cited
- → Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC(2014)220 cited
- → Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer